Your session is about to expire
← Back to Search
Anti-CD39 Antibody for Solid Tumors
Study Summary
This trial is testing a new drug for safety and how well it works in patients with cancer that has returned or not responded to other treatments.
- Advanced Solid Tumors
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a history or signs of heart problems.You are allergic to ES002023 or antibodies made from CHO (Chinese hamster ovary) cells.You are expected to live for at least 12 more weeks.You have undergone allergen desensitization therapy in the past month.You have or have had a lung disease called interstitial lung disease (ILD) or pneumonitis that needed treatment with steroids or other medicines that weaken the immune system.You have a liver or bile duct disease that is currently causing problems, except if you have Gilbert's syndrome or asymptomatic gallstones.You have advanced or spreading tumors that cannot be surgically removed. You have already tried standard treatments that didn't work or caused too many side effects.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Part 1 dose escalation
- Group 2: Part 2 dose expansion
Frequently Asked Questions
What risks could be associated with Part 1 ES002023?
"Due to its Phase 1 status, limited data supports the safety and efficacy of Part 1 ES002023. Thus, our analysts at Power assigned it a score of 1 on their scale."
What kind of results is the medical research team hoping to achieve?
"Per the sponsor of this investigation, Elpiscience Biopharma Ltd., the primary outcomes that will be assessed over a 1-3 year period is The frequency and severity of adverse events related to ES002023. In addition, secondary endpoints such as The immunogenicity of ES002023 (assessed by detecting anti-drug antibodies), Trough observed serum concentration (Ctrough)of ES002023, and The antitumor activity of ES002023 (measured via revised Response Evaluation Criteria in Solid Tumors version 1.1 [RECISTv1.1] assessments conducted by investigators"
How many sites are conducting this research project?
"Currently, 7 sites across the United States are recruiting for this medical trial. Patients may find Fayetteville, Austin and New Brunswick as well as other nearby locations convenient when considering participation in order to limit travel time."
Is recruitment still ongoing for this research project?
"According to clinicaltrials.gov, this particular trial has finished recruiting participants and is no longer seeking new enrollees. Initially posted on December 23rd 2021, it was last updated October 18th 2022. However, there are presently an additional 2503 studies actively enrolling patients at the moment."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger